Royalty Pharma targets $3.4B-$3.5B 2026 portfolio receipts as it raises guidance again (NASDAQ:RPRX)
· seekingalpha.com
Royalty Pharma (RPRX) Q2 2026 earnings call: raised guidance, strong cash flows, $1.1B deployed incl.
To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.
If you have an ad-blocker enabled you may be blocked from ...